---
title: "Roivant Sciences Ltd. (ROIV.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ROIV.US.md"
symbol: "ROIV.US"
name: "Roivant Sciences Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T06:03:07.176Z"
locales:
  - [en](https://longbridge.com/en/quote/ROIV.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ROIV.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ROIV.US.md)
---

# Roivant Sciences Ltd. (ROIV.US)

## Company Overview

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [roivant.com](https://roivant.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.71)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 201 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -56.36% |  |
| Net Profit YoY | -593.91% |  |
| P/B Ratio | 4.73 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 20189929074.77 |  |
| Revenue | 13310000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -17.11% | E |
| Profit Margin | -6079.94% | E |
| Gross Margin | -8208.15% | E |
| Revenue YoY | -56.36% | E |
| Net Profit YoY | -593.91% | E |
| Total Assets YoY | -9.79% | E |
| Net Assets YoY | -10.15% | D |
| Cash Flow Margin | 93.80% | C |
| OCF YoY | -56.36% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 4.81% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Roivant Sciences Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-56.36%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-593.91%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.73",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "20189929074.77",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "13310000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-17.11%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-6079.94%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-8208.15%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-56.36%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-593.91%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-9.79%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-10.15%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "93.80%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-56.36%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "4.81%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -24.95 | 513/386 | - | - | - |
| PB | 4.73 | 322/386 | 4.65 | 3.26 | 1.68 |
| PS (TTM) | 1516.90 | 297/386 | 1492.16 | 694.50 | 270.72 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 10 | 77% |
| Overweight | 2 | 15% |
| Hold | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 28.21 |
| Highest Target | 41.00 |
| Lowest Target | 29.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ROIV.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ROIV.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ROIV.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ROIV.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**